Market closed

Xenon Pharmaceuticals/$XENE

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Ticker

$XENE
Trading on

Industry

Biotechnology

Headquarters

Burnaby, Canada

Employees

255

XENE Metrics

BasicAdvanced
$3B
Market cap
-
P/E ratio
-$2.82
EPS
1.25
Beta
-
Dividend rate
$3B
1.25
$50.99
$28.20
388K
22.214
22.056
1.053
1.227
-21.19%
-29.75%
3.74
3.74
-18.753
5.34%
22.09%

What the Analysts think about XENE

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.

XENE Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

XENE Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XENE

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals (XENE) has a market cap of $3B as of November 22, 2024.

What is the P/E ratio for Xenon Pharmaceuticals stock?

The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of November 22, 2024.

Does Xenon Pharmaceuticals stock pay dividends?

No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Xenon Pharmaceuticals dividend payment date?

Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.

What is the beta indicator for Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.